Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.
Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.
